RHYTHM PHARMACEUTICALS, INC. Cash Flow Statement
RYTM / Health Care|11 years of annual SEC 10-K data (FY2015-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 11 fiscal years. All figures from audited SEC 10-K filings.
RHYTHM PHARMACEUTICALS, INC. used $116M in operating cash flow and negative free cash flow of $117M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.52 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$196.5M | -$260.6M | -$184.7M | -$181.1M | -$69.6M | -$134.0M | -$140.7M | -$74.1M | -$33.7M | -$25.9M | -$11.1M |
| Depreciation & Amortization | $500.0K | $700.0K | $900.0K | $896.0K | $816.0K | $690.0K | $834.0K | $442.0K | $223.0K | $144.0K | - |
| Operating Cash Flow | -$115.7M | -$113.9M | -$136.2M | -$173.4M | -$146.0M | -$122.0M | -$122.8M | -$62.1M | -$29.5M | -$23.2M | -$7.0M |
| Capital Expenditures | $953.0K | $0 | $47.0K | $281.0K | $434.0K | $214.0K | $3.4M | $722.0K | $133.0K | $1.1M | $17.0K |
| Free Cash Flow | -$116.6M | -$113.9M | -$136.2M | -$173.7M | -$146.4M | -$122.2M | -$126.1M | -$62.8M | -$29.6M | -$24.3M | -$7.0M |
| FCF Margin | -61.5% | -87.5% | -175.9% | - | - | - | - | - | - | - | - |